Human metapneumovirus (hMPV) infection in children with cancer

Area of Science:

• Pediatric Infectious Diseases
• Oncology
• Virology

Background:

• Human metapneumovirus (hMPV) is an emerging cause of severe lower respiratory tract infections (LRTI) in hospitalized children.
• Immunocompromised pediatric patients, particularly those with cancer, are at higher risk for severe hMPV-related complications.
• Understanding hMPV epidemiology and clinical outcomes in this vulnerable population is crucial for effective management.

Purpose of the Study:

• To retrospectively analyze the clinical characteristics and outcomes of hMPV infections in children diagnosed with cancer.
• To determine the incidence of upper versus lower respiratory tract involvement in this cohort.
• To evaluate the severity and management strategies for hMPV infections in immunocompromised pediatric cancer patients.

Main Methods:

• Retrospective review of 30 pediatric cancer patients with confirmed hMPV nasopharyngeal swab positivity.
• Analysis of clinical data including respiratory tract involvement, duration of illness, hospitalization, and treatment received.
• Direct fluorescent testing was used for hMPV detection.

Main Results:

• 53.3% of patients experienced upper respiratory tract infections, while 46.7% had lower respiratory tract infections.
• The median duration of respiratory illness was 6.5 days, with a 66.6% hospital admission rate.
• No patients required mechanical ventilation, and all children recovered completely; one patient needed prolonged inhaled steroid and bronchodilator therapy.

Conclusions:

• hMPV causes significant upper and lower respiratory tract infections in immunocompromised children with cancer.
• While infections can be severe, they are generally not fatal in this population.
• Symptomatic and supportive care is the recommended therapeutic approach in the absence of specific antiviral agents.